- Home
- BQ vs EDSA Comparison
BQ vs EDSA Comparison
Compare BQ & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- EDSA
- Stock Information
- Founded
- BQ 2008
- EDSA 2015
- Country
- BQ China
- EDSA Canada
- Employees
- BQ N/A
- EDSA N/A
- Industry
- BQ Other Specialty Stores
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- EDSA Health Care
- Exchange
- BQ Nasdaq
- EDSA Nasdaq
- Market Cap
- BQ 6.0M
- EDSA 6.2M
- IPO Year
- BQ 2020
- EDSA N/A
- Fundamental
- Price
- BQ $2.45
- EDSA $1.83
- Analyst Decision
- BQ
- EDSA Strong Buy
- Analyst Count
- BQ 0
- EDSA 1
- Target Price
- BQ N/A
- EDSA $21.00
- AVG Volume (30 Days)
- BQ 97.2K
- EDSA 35.8K
- Earning Date
- BQ 06-17-2025
- EDSA 05-14-2025
- Dividend Yield
- BQ N/A
- EDSA N/A
- EPS Growth
- BQ N/A
- EDSA N/A
- EPS
- BQ N/A
- EDSA N/A
- Revenue
- BQ $81,208,354.00
- EDSA N/A
- Revenue This Year
- BQ N/A
- EDSA N/A
- Revenue Next Year
- BQ N/A
- EDSA N/A
- P/E Ratio
- BQ N/A
- EDSA N/A
- Revenue Growth
- BQ N/A
- EDSA N/A
- 52 Week Low
- BQ $1.62
- EDSA $1.55
- 52 Week High
- BQ $7.40
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- BQ 58.70
- EDSA 29.28
- Support Level
- BQ $1.91
- EDSA $1.88
- Resistance Level
- BQ $2.32
- EDSA $2.05
- Average True Range (ATR)
- BQ 0.24
- EDSA 0.08
- MACD
- BQ 0.00
- EDSA -0.00
- Stochastic Oscillator
- BQ 62.77
- EDSA 0.00
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.